Pain News and Research

Latest Pain News and Research

Roche's P2X3 receptor program for chronic pain licensed to Afferent Pharmaceuticals

Roche announced today it has licensed its P2X3 receptor program aimed at developing first-in-class treatments for chronic pain to Afferent Pharmaceuticals. Afferent was co-founded by Anthony Ford, Ph.D., Pappas Ventures, and Third Rock Ventures, and is focused on developing compounds that treat chronic pain by targeting a novel biological pathway.

16 Dec 2009

Deaths from heart disease peak in December and January, US database reveals

'Tis the season… for a heart attack? According to Dr. Keith Churchwell, associate director of the Vanderbilt Heart and Vascular Institute at Vanderbilt University Medical Center, a US database of 53 million deaths occurring between 1973 and 2001 reveals that deaths from heart disease peak in December and January, with spikes on Christmas and New Year's Day.

16 Dec 2009

Pharmacy directors willing to cover tanezumab at lower prices

HealthLeaders-InterStudy and Fingertip Formulary find that 70 percent of surveyed pharmacy directors expect to cover Pfizer's tanezumab if it is approved for the treatment of chronic pain. Tanezumab, which is expected to be the first biologic approved for chronic pain and is administered intravenously under medical supervision, will likely be covered as a medical benefit rather than a pharmacy benefit according to surveyed pharmacy directors.

16 Dec 2009

Pillo1 for chronic neck and back pain

At a time when Americans spend over $50 billion on ways to alleviate neck and back pain, Dr. Raymond Hall is theorizing a painful connection between conventional pillows and neck issues and created a revolutionary solution called Pillo1 (www.pillo1.com) to address the problem.

16 Dec 2009

InSite Vision to advance new development candidate ISV-303

InSite Vision Incorporated, a company developing ophthalmic products for unmet eye care needs, today announced plans to advance new development candidate ISV-303, a topical anti-inflammatory product intended to reduce the pain and swelling associated with ocular surgery.

16 Dec 2009

Spinal Restoration receives FDA SPA concurrence letter for its Phase 3 Biostat System study

Spinal Restoration, Inc. announced today it has received a Special Protocol Assessment concurrence letter from the U.S. Food and Drug Administration (FDA) for the design of its Phase 3 study of the Biostat System for the treatment of chronic discogenic low back pain.

15 Dec 2009

Jazz Pharmaceuticals announces submission of JZP-6 NDA for treatment of fibromyalgia

Jazz Pharmaceuticals, Inc. announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for JZP-6 (sodium oxybate oral solution) for the treatment of fibromyalgia.

15 Dec 2009

Antidepressant and anti-anxiety medications linked to increased risk of cardiovascular events and death

Women with suspected coronary artery disease (CAD) who report taking antidepressant and anti-anxiety medications have an increased risk of cardiovascular events, including heart attacks and strokes, and death compared to women not taking these medications, according to researchers at the Uniformed Services University of the Health Sciences (USU).

15 Dec 2009

Florida doctor performs new, effective treatment for sinusitis

Local physician William Laskowski, MD has become the first doctor in Florida to perform an effective new treatment for sinusitis called FinESS® Sinus Treatment in an office setting. FinESS® (Entellus Medical, Maple Grove, MN) is a balloon sinuplasty option that is less-invasive than traditional sinus surgery and breaks the cycle of chronic or recurrent sinusitis with immediate relief and lasting results.

15 Dec 2009

Study explores comorbidity of medical complaints and insomnia symptoms in school-aged children

A study in the Dec. 15 issue of the Journal of Clinical Sleep Medicine indicates that significant associations exist between parent-reported insomnia symptoms and medical complaints of gastrointestinal regurgitation and headaches in young school-aged children.

15 Dec 2009

ProChon Biotech announces expansion of BioCart Cartilage Regeneration System study

ProChon Biotech, Ltd., an innovator of tissue regenerative technologies that are being developed to relieve pain and restore the mobility and quality of life for sufferers of articular cartilage injuries, today announced a significant expansion of its clinical study of the BioCart™ Cartilage Regeneration System.

15 Dec 2009

Celebrex stops aspirin from doing its job effectively

Millions of Americans take Celebrex for arthritis or other pain. Many, if they are middle-aged or older, also take a low-dose aspirin tablet daily to reduce the risk of heart attack and stroke. Yet they may be getting little protection, because Celebrex keeps the aspirin from doing its job effectively, a new study suggests.

15 Dec 2009

UCB offers tips for managing rheumatoid arthritis during festive season

A third of women living with rheumatoid arthritis say their disease impacts their enjoyment of the festive season - Women living with rheumatoid arthritis find shopping for gifts, preparing holiday food, writing cards and wrapping presents most difficult to do - Nearly two thirds of women living with rheumatoid arthritis experience pain daily

14 Dec 2009

Cell-enriched breast reconstruction procedure improves breast deformity in lumpectomy patients

Interim results from a European clinical trial, RESTORE 2, demonstrate that cell-enriched breast reconstruction achieved a high rate of patient and physician satisfaction and improvements in overall breast deformity in lumpectomy patients.

14 Dec 2009

Genentech announces positive results from Phase II study of T-DM1

Genentech, Inc., a wholly owned member of the Roche Group, today announced positive results from a Phase II study of trastuzumab-DM1 (T-DM1). As assessed by independent review, T-DM1 shrank the tumors (also known as objective response) in 33 percent of women with advanced (metastatic) HER2-positive breast cancer that had worsened following previous treatment.

14 Dec 2009

ImmunoGen announces the presentation of positive trastuzumab-DM1 clinical data

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the presentation of positive trastuzumab-DM1 (T-DM1) clinical data at the 32nd Annual San Antonio Breast Cancer Symposium (Abstract #710).

14 Dec 2009

Modified blood adult stem-cell transplant regimen reverses sickle cell disease

A modified blood adult stem-cell transplant regimen has effectively reversed sickle cell disease in 9 of 10 adults who had been severely affected by the disease, according to results of a National Institutes of Health study in the Dec. 10 issue of the New England Journal of Medicine.

13 Dec 2009

Phase 2 pivotal trial of AC220 initiated by Ambit Biosciences

Ambit Biosciences Corporation announced today the enrollment and dosing at the University of Texas M. D. Anderson Cancer Center of the first patient in the ACE (AC220 Monotherapy Efficacy) Phase 2 pivotal trial in patients with relapsed or refractory acute myeloid leukemia (AML).

11 Dec 2009

Proteins from catfish venom glands could accelerate wound healing in humans

Lest anyone have concerns about attacks of killer catfish, rest assured that, at least in North America, these finned fatales use their venom mainly to defend themselves against predatory fish, though they can inflict a painful sting that many fishermen have suffered. In other parts of the world, some catfish do have extremely toxic venoms that can be deadly to humans.

11 Dec 2009

University of Maryland School of Nursing to spearhead new Center for Pain Studies

The University of Maryland School of Nursing in Baltimore is "uniquely poised" to spearhead a new collaborative Center for Pain Studies funded by a $2.4 million, five-year federal grant, said Susan Dorsey, PhD, RN, director of the center.

11 Dec 2009

Pain News and Research

Latest Pain News and Research

Roche's P2X3 receptor program for chronic pain licensed to Afferent Pharmaceuticals

Deaths from heart disease peak in December and January, US database reveals

Pharmacy directors willing to cover tanezumab at lower prices

Pillo1 for chronic neck and back pain

InSite Vision to advance new development candidate ISV-303

Spinal Restoration receives FDA SPA concurrence letter for its Phase 3 Biostat System study

Jazz Pharmaceuticals announces submission of JZP-6 NDA for treatment of fibromyalgia

Antidepressant and anti-anxiety medications linked to increased risk of cardiovascular events and death

Florida doctor performs new, effective treatment for sinusitis

Study explores comorbidity of medical complaints and insomnia symptoms in school-aged children

ProChon Biotech announces expansion of BioCart Cartilage Regeneration System study

Celebrex stops aspirin from doing its job effectively

UCB offers tips for managing rheumatoid arthritis during festive season

Cell-enriched breast reconstruction procedure improves breast deformity in lumpectomy patients

Genentech announces positive results from Phase II study of T-DM1

ImmunoGen announces the presentation of positive trastuzumab-DM1 clinical data

Modified blood adult stem-cell transplant regimen reverses sickle cell disease

Phase 2 pivotal trial of AC220 initiated by Ambit Biosciences

Proteins from catfish venom glands could accelerate wound healing in humans

University of Maryland School of Nursing to spearhead new Center for Pain Studies

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

Pain News and Research

Latest Pain News and Research

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

Newsletters you may be interested in